DE60123939T2 - Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe - Google Patents

Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe Download PDF

Info

Publication number
DE60123939T2
DE60123939T2 DE60123939T DE60123939T DE60123939T2 DE 60123939 T2 DE60123939 T2 DE 60123939T2 DE 60123939 T DE60123939 T DE 60123939T DE 60123939 T DE60123939 T DE 60123939T DE 60123939 T2 DE60123939 T2 DE 60123939T2
Authority
DE
Germany
Prior art keywords
compound
reacting
squalamine
alpha
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123939T
Other languages
German (de)
English (en)
Other versions
DE60123939D1 (de
Inventor
A. William Plymouth Meeting KINNEY
Xuehai Plymouth Meeting ZHANG
Ronald Plymouth Meeting MICHALAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of DE60123939D1 publication Critical patent/DE60123939D1/de
Publication of DE60123939T2 publication Critical patent/DE60123939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60123939T 2000-04-12 2001-04-12 Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe Expired - Lifetime DE60123939T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19664600P 2000-04-12 2000-04-12
US196646P 2000-04-12
PCT/US2001/012004 WO2001079255A1 (en) 2000-04-12 2001-04-12 A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group

Publications (2)

Publication Number Publication Date
DE60123939D1 DE60123939D1 (de) 2006-11-30
DE60123939T2 true DE60123939T2 (de) 2007-05-31

Family

ID=22726246

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123939T Expired - Lifetime DE60123939T2 (de) 2000-04-12 2001-04-12 Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe

Country Status (12)

Country Link
US (2) US6933383B2 (cg-RX-API-DMAC10.html)
EP (1) EP1274718B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003531148A (cg-RX-API-DMAC10.html)
AT (1) ATE342912T1 (cg-RX-API-DMAC10.html)
AU (2) AU5342701A (cg-RX-API-DMAC10.html)
CA (1) CA2406847C (cg-RX-API-DMAC10.html)
CY (1) CY1105870T1 (cg-RX-API-DMAC10.html)
DE (1) DE60123939T2 (cg-RX-API-DMAC10.html)
DK (1) DK1274718T3 (cg-RX-API-DMAC10.html)
ES (1) ES2273831T3 (cg-RX-API-DMAC10.html)
PT (1) PT1274718E (cg-RX-API-DMAC10.html)
WO (1) WO2001079255A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
CN100509838C (zh) * 2004-03-31 2009-07-08 可乐丽股份有限公司 制备5α-孕烷衍生物的方法
CN100509839C (zh) * 2004-03-31 2009-07-08 可乐丽股份有限公司 制备5α-孕烷衍生物的方法
WO2005095434A1 (ja) * 2004-03-31 2005-10-13 Kuraray Co., Ltd. ５α－プレグナン誘導体の製造方法
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20070203106A1 (en) * 2005-03-31 2007-08-30 Kuraray Co., Ltd. Method for Producing 5Alpha-Pregnane Derivative
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2985271A1 (en) * 2007-09-06 2009-03-12 Ohr Pharmaceutical, Inc. A method for treating diabetes
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US20110161139A1 (en) * 2009-12-31 2011-06-30 Accenture Global Services Gmbh Capability Accelerator
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN109575096B (zh) * 2019-01-20 2021-01-01 湖南科瑞生物制药股份有限公司 一种制备16a-羟基泼尼松龙产品的新方法
CN109734765B (zh) * 2019-01-20 2021-01-01 湖南科瑞生物制药股份有限公司 一种17a-脱羟醋酸泼尼松龙产品的制备方法
CN109734764B (zh) * 2019-01-20 2021-01-01 湖南科瑞生物制药股份有限公司 一种17a-脱羟醋酸泼尼松龙的制备方法
CN109651475B (zh) * 2019-01-20 2021-01-01 湖南科瑞生物制药股份有限公司 一种制备16a-羟基泼尼松龙的新方法
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
CN113621016B (zh) * 2021-09-06 2022-05-17 北京泛球生物科技有限公司 一种地屈孕酮关键中间体的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016390A (en) 1960-06-30 1962-01-09 Searle & Co N-(substituted alkyl) amino-5alpha-androstan-17beta-ols
US3370070A (en) 1965-06-16 1968-02-20 Searle & Co [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones
GB1565351A (en) 1975-06-02 1980-04-16 Theramex Steroid aminoethers
US4220598A (en) 1977-11-14 1980-09-02 Abbott Laboratories Method and reagents for measuring the level of conjugated bile acids
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US4301246A (en) * 1979-04-12 1981-11-17 Hoffmann-La Roche Inc. Process for chenodeoxycholic acid production
US4230625A (en) * 1979-04-12 1980-10-28 Hoffmann-La Roche Inc. Process for chenodeoxycholic acid and intermediates therefore
US4372888A (en) 1980-08-26 1983-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Nondenaturing zwitterionic detergents
JPS5842878B2 (ja) 1981-12-02 1983-09-22 名糖産業株式会社 １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用
DE3366932D1 (en) 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IT1221734B (it) 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US4545938A (en) 1983-11-02 1985-10-08 Beth Israel Medical Center Chemical synthesis
EP0243449A1 (en) 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPS62175497A (ja) 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
US5075464A (en) 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
IT1229569B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1229570B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
JPH07116215B2 (ja) 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US4966897A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5004737A (en) 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
CA2081205C (en) 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
US5250524A (en) 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5247104A (en) 1992-11-04 1993-09-21 Wisconsin Alumni Research Foundation Preparation of 1α, 24-dihydroxyvitamin D analogs
JPH06329679A (ja) 1993-01-20 1994-11-29 Nissan Chem Ind Ltd 光学活性β−アミノアルコキシボラン錯体
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
CA2157594A1 (en) 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
WO1994024800A1 (en) 1993-04-12 1994-10-27 Unisys Corporation Portable adapter for portable pc
DK0749437T3 (da) 1994-03-10 2002-03-04 Magainin Pharma Farmaceutisk anvendelse af steroidderivater
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
AU723663C (en) 1995-06-07 2001-11-01 Magainin Pharmaceuticals, Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds
US6262283B1 (en) * 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds

Also Published As

Publication number Publication date
AU2001253427B2 (en) 2007-02-08
EP1274718B1 (en) 2006-10-18
US6933383B2 (en) 2005-08-23
JP2003531148A (ja) 2003-10-21
WO2001079255A1 (en) 2001-10-25
US20030171576A1 (en) 2003-09-11
AU5342701A (en) 2001-10-30
US7728157B2 (en) 2010-06-01
ES2273831T3 (es) 2007-05-16
PT1274718E (pt) 2007-01-31
CY1105870T1 (el) 2011-02-02
DE60123939D1 (de) 2006-11-30
ATE342912T1 (de) 2006-11-15
US20050187202A1 (en) 2005-08-25
CA2406847A1 (en) 2001-10-25
DK1274718T3 (da) 2007-02-12
CA2406847C (en) 2009-11-17
EP1274718A1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
DE3348322C2 (cg-RX-API-DMAC10.html)
DE2954557C2 (cg-RX-API-DMAC10.html)
DE2463203C2 (cg-RX-API-DMAC10.html)
EP1274718B1 (en) A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
DE69020605T2 (de) 1 alpha,25-Dihydroxyvitamin-D4-Verbindungen, Ergosta-5,7-dien-Verbindungen und Verfahren zu deren Herstellung.
DE102006047173B4 (de) Verfahren zur Herstellung eines Analogons von Vitamin D
AU2001253427A1 (en) A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
DE112021003885T5 (de) VERFAHREN ZUR HERSTELLUNG VON (3α,5α)-3-HYDROXY-3-METHYL-PREGNAN-20-ON (GANAXOLON)
DE2746107A1 (de) Pregnanderivate
DE60310723T2 (de) Verfahren und neue zwischenprodukte für die herstellung von sterolen mit einer progesteronischen aktivität
DE69005709T2 (de) Adduktaldehyd und seine Anwendung in der Herstellung von Vitamin-D-Derivaten.
CH620227A5 (cg-RX-API-DMAC10.html)
DE2617295C2 (de) Verfahren zur Herstellung von Spiroverbindungen der Steroidreihe
DE1568308A1 (de) Verfahren zur Herstellung von delta4,9,11-Trienen der 19-Nor-androstanreihe
US5391777A (en) Isolation of steroids containing a 5,7-diene functionality from a sterol mixture
EP0039861B1 (de) Verfahren zum Abbau der 20-Carboxylgruppe in delta-1,4-BNC und verwandten Steroidverbindungen sowie neue stickstoffhaltige C-21-Steroidverbindungen
EP0039893B1 (de) Verfahren zum Abbau der C-20-Carboxylgruppe in delta-4- und gegebenenfalls weitere Doppelbindungen enthaltenden BNC-Verbindungen sowie neue C-21-Steroide
DE3511716C2 (cg-RX-API-DMAC10.html)
DE69326972T2 (de) Verfahren zur Herstellung eines optisch aktiven Olefins
DE3712586C2 (cg-RX-API-DMAC10.html)
EP0039895B1 (de) Neue Pregnan-20-Carbonsäurederivate und Verfahren zu ihrer Herstellung
EP0019162B1 (de) 12-alpha-Hydroxysteroide und deren Herstellung
EP0040347B1 (de) Neue Steroid-20-carbonsäureverbindungen und Verfahren zu ihrer Herstellung
DE964775C (de) Verfahren zur Herstellung von Steroid-17-carbonsaeuren bzw. von Steroid-17-ketonen
DD250537A1 (de) Verfahren zur herstellung von 3-substituierten 5 beta, 6 beta-epoxy-1,2-dehydrosteroiden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1274718

Country of ref document: EP